Antonis C Antoniou

List of Publications by Year
in descending order

199 papers	23,004 citations	12322 69 h-index	9579 142 g-index
213 all docs	213 docs citations	213 times ranked	21167 citing authors

#	Article	IF	Citations
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
2	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
3	Polygenic susceptibility to breast cancer and implications for prevention. Nature Genetics, 2002, 31, 33-36.	9.4	874
4	Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257.	13.9	764
5	Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. Journal of the National Cancer Institute, 2013, 105, 812-822.	3.0	753
6	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	13.9	745
7	Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1748-1757.	0.8	641
8	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
9	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
10	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
11	Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, 2011, 43, 879-882.	9.4	460
12	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine, 2019, 21, 1708-1718.	1.1	415
13	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
14	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	9.4	357
15	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
16	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 404-412.	1.1	341
17	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	311
18	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€"negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309

#	Article	IF	Citations
19	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
20	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. European Urology, 2015, 68, 186-193.	0.9	279
21	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	1.1	278
22	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
23	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
24	Improving reporting standards for polygenic scores in risk prediction studies. Nature, 2021, 591, 211-219.	13.7	265
25	Evidence for further breast cancer susceptibility genes in addition toBRCA1 andBRCA2 in a population-based study. Genetic Epidemiology, 2001, 21, 1-18.	0.6	263
26	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
27	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
28	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
29	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
30	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
31	Germline RAD51C mutations confer susceptibility to ovarian cancer. Nature Genetics, 2012, 44, 475-476.	9.4	219
32	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
33	Polygenic inheritance of breast cancer: Implications for design of association studies. Genetic Epidemiology, 2003, 25, 190-202.	0.6	213
34	Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). Journal of the National Cancer Institute, 2006, 98, 535-544.	3.0	191
35	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178
36	Tumour risks and genotypeâ€"phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD. Journal of Medical Genetics, 2018, 55, 384-394.	1.5	177

#	Article	IF	Citations
37	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
38	Risk models for familial ovarian and breast cancer. , 2000, 18, 173-190.		157
39	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
40	Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 2013, 31, 3091-3099.	0.8	148
41	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	1.5	148
42	Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	3.2	138
43	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. Journal of the National Cancer Institute, 2018, 110, 714-725.	3.0	138
44	Oral Contraceptives and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study: A Report From EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. Journal of Clinical Oncology, 2007, 25, 3831-3836.	0.8	137
45	A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genetic Epidemiology, 2005, 29, 1-11.	0.6	136
46	An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Research, 2007, 9, 104.	2.2	136
47	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 601-610.	1.1	130
48	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
49	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. European Urology, 2020, 77, 24-35.	0.9	124
50	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
51	Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Research, 2006, 66, 1866-1872.	0.4	119
52	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Human Molecular Genetics, 2016, 25, 2256-2268.	1.4	106
53	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Journal of the National Cancer Institute, 2020, 112, 1242-1250.	3.0	106
54	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105

#	Article	IF	Citations
55	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
56	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
57	CanRisk Toolâ€"A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 469-473.	1.1	98
58	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
59	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
60	The future of early cancer detection. Nature Medicine, 2022, 28, 666-677.	15.2	92
61	The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain. Clinical Cancer Research, 2008, 14, 2861-2869.	3.2	90
62	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
63	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	0.8	90
64	Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predictingBRCA1/2mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. Journal of Medical Genetics, 2013, 50, 360-367.	1.5	88
65	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
66	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
67	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nature Communications, 2020, 11, 3833.	5.8	88
68	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry, 2020, 25, 2392-2409.	4.1	83
69	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
70	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genetics in Medicine, 2016, 18, 1190-1198.	1.1	80
71	Risk prediction models for familial breast cancer. Future Oncology, 2006, 2, 257-274.	1.1	78
72	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78

#	Article	IF	Citations
73	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
74	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Research, 2005, 8, R3.	2.2	75
75	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics, 2014, 51, 98-107.	1.5	74
76	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
77	Parity and breast cancer risk among BRCA1 and BRCA2mutation carriers. Breast Cancer Research, 2006, 8, R72.	2.2	66
78	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 740-746.	1.1	63
79	Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocrine-Related Cancer, 2016, 23, T69-T84.	1.6	63
80	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American Journal of Obstetrics and Gynecology, 2017, 217, 578.e1-578.e12.	0.7	63
81	Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Research, 2010, 12, R28.	2.2	62
82	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). Journal of Personalized Medicine, 2021, 11, 511.	1.1	59
83	Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. Journal of Medical Genetics, 2014, 51, 108-113.	1.5	58
84	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
85	Specifying the ovarian cancer risk threshold of â€˜premenopausal risk-reducing salpingo-oophorectomyâ€™ for ovarian cancer prevention: a cost-effectiveness analysis. Journal of Medical Genetics, 2016, 53, 591-599.	1.5	57
86	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	1.1	56
87	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
88	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53
89	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genetics in Medicine, 2017, 19, 30-35.	1.1	53
90	A risk prediction algorithm for ovarian cancer incorporatingBRCA1, BRCA2, common alleles and other familial effects. Journal of Medical Genetics, 2015, 52, 465-475.	1.5	52

#	Article	IF	Citations
91	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
92	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research, 2018, 20, 132.	2.2	51
93	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
94	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. Genetics in Medicine, 2020, 22, 1803-1811.	1.1	49
95	Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Research, 2021, 23, 22.	2.2	49
96	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
97	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
98	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
99	Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. Journal of Medical Genetics, 2018, 55, 538-545.	1.5	45
100	Assessing and managing breast cancer risk: Clinicians' current practice and future needs. Breast, 2014, 23, 644-650.	0.9	44
101	Risk Prediction Models for Colorectal Cancer Incorporating Common Genetic Variants: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1580-1593.	1.1	44
102	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. International Journal of Epidemiology, 2022, 50, 1897-1911.	0.9	43
103	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
104	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	2.2	41
105	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
106	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
107	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. PLoS ONE, 2020, 15, e0229999.	1.1	40
108	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39

#	Article	IF	Citations
109	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	1.5	38
110	RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors. Journal of Clinical Investigation, 2021, 131, .	3.9	38
111	Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of Highâ€Risk Mutations. Genetic Epidemiology, 2012, 36, 274-291.	0.6	37
112	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
113	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
114	Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. Journal of Medical Genetics, 2018, 55, 97-103.	1.5	34
115	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	0.7	34
116	Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Research, 2010, 12, R10.	2.2	33
117	iPreventÂ®: a tailored, web-based, decision support tool for breast cancer risk assessment and management. Breast Cancer Research and Treatment, 2016, 156, 171-182.	1.1	33
118	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	1.4	33
119	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Journal of Medical Genetics, 2022, 59, 632-643.	1.5	33
120	Rare coding variants and X-linked loci associated with age at menarche. Nature Communications, 2015, 6, 7756.	5.8	32
121	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. American Journal of Obstetrics and Gynecology, 2018, 218, 431.e1-431.e12.	0.7	32
122	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. Journal of Medical Genetics, 2019, 56, 347-357.	1.5	32
123	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
124	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
125	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
126	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28

#	Article	IF	Citations
127	Homeobox B13 G84E Mutation and Prostate Cancer Risk. European Urology, 2019, 75, 834-845.	0.9	28
128	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist, 2016, 21, 716-722.	1.9	27
129	Chromatin interactome mapping at 139 independent breast cancer risk signals. Genome Biology, 2020, 21, 8.	3.8	27
130	Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genetics in Medicine, 2022, 24, 586-600.	1.1	27
131	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
132	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. European Journal of Human Genetics, 2017, 25, 432-438.	1.4	26
133	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
134	Common genetic variants and cancer risk in Mendelian cancer syndromes. Current Opinion in Genetics and Development, 2010, 20, 299-307.	1.5	25
135	External Validation of Risk Prediction Models Incorporating Common Genetic Variants for Incident Colorectal Cancer Using UK Biobank. Cancer Prevention Research, 2020, 13, 509-520.	0.7	25
136	A New Comprehensive Colorectal Cancer Risk Prediction Model Incorporating Family History, Personal Characteristics, and Environmental Factors. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 549-557.	1.1	25
137	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	1.1	24
138	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
139	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
140	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	1.4	21
141	Non-coding RNAs underlie genetic predisposition to breast cancer. Genome Biology, 2020, 21, 7.	3.8	21
142	Performance of Breast Cancer Polygenic Risk Scores in 760 FemaleCHEK2Germline Mutation Carriers. Journal of the National Cancer Institute, 2021, 113, 893-899.	3.0	21
143	Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer. European Journal of Human Genetics, 2014, 22, 1330-1333.	1.4	20
144	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 44-56.	1.8	19

#	Article	IF	Citations
145	The BRCA2 c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	1.1	19
146	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
147	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers, 2020, 12, 1241.	1.7	19
148	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
149	Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models. JNCI Cancer Spectrum, 2021, 5, pkab021.	1.4	19
150	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
151	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
152	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
153	BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis. British Journal of Cancer, 2022, 126, 1067-1081.	2.9	18
154	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. Australian Journal of Primary Health, 2016, 22, 255.	0.4	16
155	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
156	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582.	1.1	15
157	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. BJU International, 2022, 129, 325-336.	1.3	15
158	Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1542-1551.	0.8	14
159	Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1018-1024.	1.1	13
160	Epidemiology of ATTRV30M neuropathy in Cyprus and the modifier effect of complement C1q on the age of disease onset. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 220-226.	1.4	12
161	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
162	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. JMIR Formative Research, 2018, 2, e24.	0.7	10

#	Article	IF	Citations
163	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	1.1	10
164	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 2022, 14, 2716.	1.7	10
165	Clinical software development for the Web: lessons learned from the BOADICEA project. BMC Medical Informatics and Decision Making, 2012, 12, 30.	1.5	9
166	Breast cancer risk in women with PALB2 mutations in different populations. Lancet Oncology, The, 2015, 16, e375-e376.	5.1	9
167	pedigreejs: a web-based graphical pedigree editor. Bioinformatics, 2018, 34, 1069-1071.	1.8	9
168	Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. Familial Cancer, 2018, 17, 31-41.	0.9	9
169	Potential of polygenic risk scores for improving population estimates of womenâ€™s breast cancer genetic risks. Genetics in Medicine, 2021, 23, 2114-2121.	1.1	9
170	Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. BMC Medicine, 2022, 20, 150.	2.3	9
171	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. JNCI Cancer Spectrum, 2019, 3, pkz066.	1.4	8
172	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. Journal of Personalized Medicine, 2021, 11, 916.	1.1	8
173	Cliniciansâ€™ use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. Journal of Community Genetics, 2019, 10, 61-71.	0.5	7
174	Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. Human Mutation, 2021, 42, 1488-1502.	1.1	7
175	Prospective Evaluation over 15 Years of Six Breast Cancer Risk Models. Cancers, 2021, 13, 5194.	1.7	7
176	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Journal of the National Cancer Institute, 2022, 114, 540-552.	3.0	7
177	Immune Cell Associations with Cancer Risk. IScience, 2020, 23, 101296.	1.9	6
178	Prostate Cancer Risk by BRCA2 Genomic Regions. European Urology, 2020, 78, 494-497.	0.9	6
179	Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate DUSP4. Cancers, 2020, 12, 170.	1.7	6
180	Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses. Npj Breast Cancer, 2021, 7, 46.	2.3	6

#	Article	IF	Citations
181	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	2.3	5
182	Letter to the editor: a response to Mingâ€™s study on machine learning techniques for personalized breast cancer risk prediction. Breast Cancer Research, 2020, 22, 17.	2.2	4
183	Characterisation of protein-truncating and missense variants in PALB2 in 15 768 women from Malaysia and Singapore. Journal of Medical Genetics, 2021, , jmedgenet-2020-107471.	1.5	4
184	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. Diagnostics, 2022, 12, 1028.	1.3	3
185	Reply to V. Fallet et al. Journal of Clinical Oncology, 2022, 40, 2509-2510.	0.8	3
186	Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention. Preventive Medicine, 2022, 159, 107075.	1.6	3
187	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. Journal of Clinical Oncology, 2013, 31, e20660-e20660.	0.8	2
188	Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer.. Journal of Clinical Oncology, 2013, 31, 29-29.	0.8	2
189	Risk models for familial ovarian and breast cancer. Genetic Epidemiology, 2000, 18, 173.	0.6	1
190	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. Journal of Clinical Oncology, 2013, 31, 17-17.	0.8	1
191	BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer.. Journal of Clinical Oncology, 2012, 30, 1545-1545.	0.8	0
192	Profile study: Genetic prostate cancer risk stratification for targeted screening.. Journal of Clinical Oncology, 2013, 31, 5054-5054.	0.8	0
193	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. Journal of Clinical Oncology, 2013, 31, 1559-1559.	0.8	0
194	The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.. Journal of Clinical Oncology, 2014, 32, 22-22.	0.8	0
195	Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study.. Journal of Clinical Oncology, 2017, 35, 1558-1558.	0.8	0
196	Title is missing!. , 2020, 15, e0229999.		0
197	Title is missing!. , 2020, 15, e0229999.		0
198	Title is missing!. , 2020, 15, e0229999.		0

#	Article	IF	Citations
199	Title is missing!. , 2020, 15, e0229999.		0